Amneal Pharmaceuticals, Inc. (AMRX) income statement
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.88+0.76 (+3.60%)
Close on Nov 18, 2026Market cap $6.99BP/E 44.7Yield –
Amneal Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 39.3%
- Operating margin
- 14.6%
- Net margin
- 5.0%
- Return on equity, FY2025
- -80.0%
Financial strength
- Current ratio
- 2.20
- Debt to equity
- 77.83
- Debt to assets
- 68.1%
- Cash to current liabilities
- 14.5%
Valuation
- P/E ratio
- 44.7
- Price to sales
- 2.24
- Price to book
- 211.59
- Dividend yield
- –
See a number that looks wrong?